Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
复制标题
DOI：
10.1002/ajh.23795
复制
发表时间：
2014-10
影响因子：
12.8
通讯作者：
Kantarjian, Hagop
中科院分区：
文献类型：
--
作者：
Borthakur, Gautam;Cortes, Jorge E.;Estey, Elihu E.;Jabbour, Elias;Faderl, Stefan;O'Brien, Susan;Garcia-Manero, Guillermo;Kadia, Tapan Mahendra;Wang, Xuemei;Patel, Keyur;Luthra, Rajyalakshmi;Koller, Charles;Brandt, Mark;Ravandi, Farhad;Kantarjian, Hagop
尽管被认为是“高风险”的急性髓性白血病（AML），但核心结合因子（CBF） AML的长期预后表明仍有改善的空间。我们报道了一种由氟达拉滨、阿糖胞苷、粒细胞集落刺激因子和低剂量吉图珠单抗ozogamicin （FLAG-GO）组成的方案，作为CBF AML患者的一线治疗。45例患者入组（中位年龄48岁）。缓解率为95%，诱导死亡为5%。3年总生存期（OS）和无复发生存期（RFS）概率分别为78%和85%。FLAG-GO方案导致CBF AML的高RFS和OS率。我们的数据以及最近来自几个大型研究小组的数据强烈支持将吉妥珠单抗ozogamicin纳入CBF AML的一线方案。
Despite being considered “good-risk” acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.
登录
查看更多内容
影响因子：
2.7
作者：
Park, Sang Hyuk;Chi, Hyun-Sook;Park, Chan-Jeoung
通讯作者：
Park, Chan-Jeoung
影响因子：
6.2
作者：
Borthakur G;Kantarjian H;Wang X;Plunkett WK Jr;Gandhi VV;Faderl S;Garcia-Manero G;Ravandi F;Pierce S;Estey EH
通讯作者：
Estey EH
影响因子：
20.3
作者：
Jourdan, Eric;Boissel, Nicolas;Dombret, Herve
通讯作者：
Dombret, Herve
影响因子：
45.3
作者：
Marcucci, G;Mrózek, K;Bloomfield, CD
通讯作者：
Bloomfield, CD
影响因子：
11.4
作者：
Goemans, BF;Zwaan, CM;Heinrich, MC
通讯作者：
Heinrich, MC